The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials

Purpose. The purpose of this meta-analysis was to evaluate the efficacy and safety of dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular edema (DME) with retinal vein occlusion secondary to macular edema (RVO-ME). Materials and Methods. Relevant databases were searched to...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ophthalmology 2022-08, Vol.2022, p.1-11
Main Authors: Xiaodong, Li, Xuejun, Xie
Format: Article
Language:English
Subjects:
Analysis
Bias
Central nervous system depressants
Clinical trials
Dexamethasone
Diabetes
Diabetic retinopathy
Dropsy
Drug therapy
Edema
Evidence-based medicine
Fludrocortisone
Glaucoma
Meta-analysis
Retinal diseases
Steroids
Transplants & implants
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose. The purpose of this meta-analysis was to evaluate the efficacy and safety of dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular edema (DME) with retinal vein occlusion secondary to macular edema (RVO-ME). Materials and Methods. Relevant databases were searched to include randomized controlled trials (RCTs) evaluating DEX for DME and RVO-ME. The search was conducted until March 2022. Meta-analysis was performed using Rev Man 5.4.1 software after screening the literature by inclusion and exclusion criteria, extracting information, and evaluating the methodological quality of the included studies. Results. The study showed that DEX treatment of RVO-ME was associated with an improvement in best corrected visual acuity (BCVA) (MD = −9.08, 95% CI: −10.89–7.27, P
ISSN:2090-004X
2090-0058
DOI:10.1155/2022/4007002